Topical pain product – Combines a dimethyl sulfoxide (DMSO) based transdermal carrier with 2% diclofenac sodium, a leading NSAID
Indication
- Treating the pain of osteoarthritis of the knee
Benefits
- Low systemic exposure to minimize side effects
- First twice per day dosing topical NSAID in the U.S.
- Metered dose dispenser
Commercial Status
- Marketed in the U.S. by Horizon Pharma plc – January 2015
Intellectual Property
- Patents issued in nineteen countries (ex-U.S.) and pending in five countries with the latest expiring 2027
- Pennsaid Pump patent applications pending in eleven countries through 2033
Website
- U.S.: www.pennsaid.com